Medical/Pharmaceuticals
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited
2024-01-03 20:00
7255
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...
2024-01-03 19:37
4360
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...
2024-01-03 18:10
6721
Bangkok Dusit Medical Services strengthens partnership with CNN focusing on global health issues and solutions
HONG KONG, Jan. 3, 2024 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest private healthcare network inThailand, is
continuing its long-term partnership with CNN International Commercial (CNNIC)
through the sponsorship ofVital Signs
2024-01-03 11:30
3628
Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China
* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo * In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c< ...
2024-01-03 10:00
4216
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a US andChina-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license agreement with A...
2024-01-02 22:00
3078
Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with Ease
LOS ANGELES, Jan. 2, 2024 /PRNewswire/ -- A recent study published in the Clinical, Cosmetic and Investigational Dermatology journal reveals a groundbreaking advancement in hair transplantation, reports Dr U Hair and Skin Clinic. The research, titled "No-Shave Long Hair Follicular Unit Excision u...
2024-01-02 21:00
2763
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval ...
2024-01-02 20:30
3541
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...
2024-01-02 20:06
4679
Xinhua Silk Road: Xinhua-Yushu Wild Cordyceps Sinensis Price Index unveiled in Beijing
BEIJING, Jan. 2, 2024 /PRNewswire/ -- The Xinhua-Yushu Wild Cordyceps Sinensis
Price Index was officially released on Dec. 27th inBeijing, capital of China,
indicating the accelerated development of wild cordyceps sinensis industry
towards a new stage of digital, information and modern mode.
2024-01-02 10:06
4220
Demron by RST - Advanced Protection Against Today's Nuclear Threats
MIAMI, Jan. 2, 2024 /PRNewswire/ -- Radiation Shield Technologies (RST) proudly marks over two decades of innovation with Demron, a unique fabric designed to safeguard frontline personnel, including military, nuclear industry workers, emergency response teams, Hazmat Teams, firefighters, law enfo...
2024-01-02 08:00
3368
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...
2024-01-02 08:00
11882
ANAESTHESIOLOGIST HERO, DOCTOR'S QUICK THINKING SAVES CYCLIST'S LIFE DURING LEKAS NIGHT RIDE 2023
Off-duty doctor's decisive action and collaboration with fellow physician-cyclists lead to a successful resuscitation and life-saving measures. SELANGOR, MALAYSIA, Dec. 29, 2023 /PRNewswire/ -- In an extraordinary display of quick thinking and medical expertise, Dr. Shahridan Bin Mohd Fathil, an ...
2023-12-29 17:20
4074
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive...
2023-12-29 12:33
5188
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses through at least 3-weeks-- --Durable efficacy and PK profile expected to support convenient dosing interval of ≥2-weeks, compared to daily or weekly d...
2023-12-29 07:30
4486
HANSIZHUANG Sets Sail in Indonesia Market
* The 1st China anti-PD-1 monoclonal antibody successfully approved in Southeast Asia - * The 1st overseas approval of HANSIZHUANG, highlighting another major milestone of Henlius' global strategy after HANQUYOU - * Along with KGbio and other partners to develop and launch HANSIZHUANG in ov...
2023-12-28 21:51
5782
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-12-28 15:45
3515
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-12-28 08:00
5223
Visionary Excellence Recognized: VISTA Eye Specialist Clinches Top Honor at Health and Wellness Brand Awards
PETALING JAYA, Malaysia, Dec. 28, 2023 /PRNewswire/ -- VISTA Eye Specialist ('VISTA'),Malaysia's premier eye care group, proudly announces its recent accolade: the coveted Malaysia Health and Wellness Brand Awards ('Award') in the Health Institutions Category for the 4th time. The Award, organize...
2023-12-28 08:00
3289
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovat...
2023-12-27 20:50
5147
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
58123
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
52850
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
51202
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
20636
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
15883